Use of inhibitors of Bruton's tyrosine kinase (Btk)
Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
1. A method for treating chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in an individual who has failed at least one prior therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma comprising administering to the individual once per day about 420 mg of an oral dose of an inhibitor of Bruton's tyrosine kinase (Btk) having the structure:
2. The method of claim 1 , wherein the oral dose is a capsule.
3. The method of claim 1 , wherein, following administration of the inhibitor, the individual achieves a stable disease, a partial response, or a complete response.
4. The method of claim 1 , wherein, following administration of the inhibitor, the individual achieves a partial response or a complete response.
5. The method of claim 1 , wherein, following administration of the inhibitor, the individual achieves a complete response.
6. The method of claim 1 , wherein, following administration of the inhibitor, the individual does not experience a progressive disease.
7. The method of claim 3 , wherein the method is a method of treating chronic lymphocytic leukemia (CLL).
8. The method of claim 3 , wherein the method is a method of treating small lymphocytic lymphoma (SLL).
9. The method of claim 1 , wherein the individual has nucleic acid deletion in chromosome 17.
10. The method of claim 9 , wherein the deletion is in 17p.
11. A method for treating relapsed or refractory chronic lymphocytic leukemia (CLL)/relapsed or refractory small lymphocytic lymphoma (SLL) in an individual comprising administering to the individual in need thereof once per day about 420 mg of an oral dose of an inhibitor of Bruton's tyrosine kinase (Btk) having the structure:
12. The method of claim 11 , wherein the oral dose is a capsule.
13. The method of claim 11 , wherein, following administration of the inhibitor, the individual achieves a stable disease, a partial response, or a complete response.
14. The method of claim 11 , wherein, following administration of the inhibitor, the individual achieves a partial response or a complete response.
15. The method of claim 11 , wherein, following administration of the inhibitor, the individual achieves a complete response.
16. The method of claim 11 , wherein, following administration of the inhibitor, the individual does not experience a progressive disease.
17. The method of claim 13 , wherein the method is a method of treating relapsed or refractory chronic lymphocytic leukemia (CLL).
18. The method of claim 13 , wherein the method is a method of treating relapsed or refractory small lymphocytic lymphoma (SLL).
19. The method of claim 11 , wherein the individual has nucleic acid deletion in chromosome 17.
20. The method of claim 19 , wherein the deletion is in 17p.
21. A method for treating small lymphocytic lymphoma (SLL) in an individual who has failed at least one prior therapy for small lymphocytic lymphoma comprising administering to the individual once per day about 420 mg of an oral dose of an inhibitor of Bruton's tyrosine kinase (Btk) having the structure:
22. The method of claim 21 , wherein, following administration of the inhibitor, the individual achieves a partial response or a complete response.
23. The method of claim 21 , wherein, following administration of the inhibitor, the individual achieves a complete response.
24. The method of claim 21 , wherein, following administration of the inhibitor, the individual does not experience a progressive disease.
25. The method of claim 21 , wherein the individual has nucleic acid deletion in chromosome 17p.
26. A method for treating relapsed or refractory small lymphocytic lymphoma (SLL) in an individual comprising administering to the individual in need thereof once per day about 420 mg of an oral dose of an inhibitor of Bruton's tyrosine kinase (Btk) having the structure:
27. The method of claim 26 , wherein, following administration of the inhibitor, the individual achieves a partial response or a complete response.
28. The method of claim 26 , wherein, following administration of the inhibitor, the individual achieves a complete response.
29. The method of claim 26 , wherein, following administration of the inhibitor, the individual does not experience a progressive disease.
30. The method of claim 26 , wherein the individual has nucleic acid deletion in chromosome 17p.